Floatz logo

TEGAFUR

Efficacy and Safety

The First Affiliated Hospital with Nanjing Medical UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Efficacy and Safety cohort.

Asset / SponsorPhaseRating
Huazhi Rougan Granule
Shandong New Time Pharmaceutical Co., LTD
Phase 4BB
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 4BB
Inno-206
Women's Hospital School Of Medicine Zhejiang University
Phase 4BB
Rivoceranib
Rongjie Tao
Phase 2B
Catequentinib
Sun Yat-sen University
Phase 2CCC

View all 14 →

Same molecule, other indications

TEGAFUR is also rated in:

rectal cancerDormant
B
Indicative ·
59 / 100
View asset →
cervical intraepithelial neoplasia grade 2/3Dormant
B
Indicative ·
59 / 100
View asset →
Adjuvant ChemotherapyDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →